Literature DB >> 29459429

14-year case series of eyelid sebaceous gland carcinoma in Chinese patients and review of management.

Stacey C Lam1,2, Emmy Y M Li1,2, Hunter K L Yuen1,2.   

Abstract

AIMS: Sebaceous gland carcinoma (SGC) of the eyelid is a rare but potentially deadly cancer. The purpose of this study was to determine whether the American Joint Committee on Cancer (AJCC) 7th Edition T category for SGC correlated with metastasis and survival in the Chinese population.
METHODS: This was a retrospective, single-centre cohort study. Patients with surgically resected eyelid SGC between January 2001 and May 2015 at the Hong Kong Eye Hospital were reviewed. Tumours were staged using the AJCC criteria. The main outcome measures included local recurrence, metastasis and death. Disease-free survival (DFS) was measured from the completion of treatment; overall survival was measured from the date of initial diagnosis.
RESULTS: The study included 22 Chinese patients with a mean age of 65.4 years. The majority presented as a nodular lesion (91%) with 12 eyes (54.5%) initially misdiagnosed and a mean presentation time of 1 year. It was found that those with AJCC stage T2b or higher were significantly associated with lymph node metastasis (P=0.002) when compared with those with stage T2a. Older age at diagnosis (P=0.035) and no misdiagnosis (P=0.025) were associated with shorter DFS. Those with stage 3a or higher were associated with shorter DFS (P=0.007) and overall survival (P=0.024).
CONCLUSION: Similar to previous reports, in this Chinese cohort, AJCC staging for SGC correlated with lymph node metastasis, DFS and overall survival. Those with stage 2b or higher on presentation will need closer surveillance for lymph node metastasis and may benefit from sentinel lymph node biopsy. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  AJCC; Hong Kong; lymph node metastasis; malignant eyelid tumour; sebaceous carcinoma

Mesh:

Year:  2018        PMID: 29459429     DOI: 10.1136/bjophthalmol-2017-311533

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  4 in total

1.  The practice patterns in the management of sebaceous carcinoma of the eyelid in the Asia Pacific region.

Authors:  Janice J C Cheung; Bita Esmaeli; Stacey C Lam; Tracey Kwok; Hunter K L Yuen
Journal:  Eye (Lond)       Date:  2019-04-05       Impact factor: 3.775

2.  Clinical Features and Prognosis of Young and Middle-Aged Adults With Skin Sebaceous Adenocarcinoma.

Authors:  Fan Wang; Xiu-Yun Wang; Xian Jiang
Journal:  Dermatol Surg       Date:  2022-06-21       Impact factor: 2.914

3.  Outcome after treatment for sebaceous carcinoma: A multicenter study.

Authors:  Eva Huis In 't Veld; Ronald Keizer; Nicoline Post; Jeroen Versteeg; Robert Verdijk; Nicole Naus; Germaine Relyveld; Marianne Crijns; Myles Smith; Dirk Grünhagen; Marlies Wakkee; Dion Paridaens; Ioannis Zavrakidis; Antien Mooyaart; Alexander van Akkooi; Dirk Strauss; Cornelis Verhoef; Michel Wouters; Andrew Hayes; Winan van Houdt
Journal:  J Surg Oncol       Date:  2022-01-06       Impact factor: 2.885

4.  Nordic treatment practices survey and consensus for treatment of eyelid sebaceous carcinoma.

Authors:  Tiina Leivo; Johanna Sarmela; Maria Enckell-Aaltonen; Eva Dafgård Kopp; Caroline Schmitt; Peter B Toft; Haraldur Sigurdsson; Marita Uusitalo
Journal:  BMC Ophthalmol       Date:  2020-03-16       Impact factor: 2.209

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.